Masayoshi Yamaguchi, PhD, IOM, FAOE

Masayoshi Yamaguchi, PhD, IOM, FAOE

This email address is being protected from spambots. You need JavaScript enabled to view it. | (808) 440-4595

Associate Member, Cancer Biology Program, University of Hawaiʻi Cancer Center

Academic Appointment(s):
Professor (Researcher), University of Hawaiʻi Cancer Center, University of Hawaiʻi at Mānoa

1976 – PhD, Shizuoka College of Pharmacy, Shizuoka, Japan
1973 – MS, Shizuoka College of Pharmacy, Shizuoka, Japan – 1986 – reorganized in the University of Shizuoka, School of Pharmaceutical Sciences, Shizuoka, Japan


1971 – Pharmacist license (Japan, Registered No. 354325)
1971 – Clinical Inspector license (Japan, Registered No. 141855)


2022 – Full member, Sigma Xi (The Scientific Research Honor Society)
2021 – Advisory Board Members, The USERN (Universal Scientific Education and Research Network)
2017 – The 2017 Albert Nelson Marquis Lifetime Achievement Award, (Marquis Who's Who, USA)
2023 – Founding Editor-in-Chief, Current Cell Science
2022 – Editorial Board member (Editor), Discover Oncology
2021 – Co-Editor-in-Chief, Current Cancer Drug Target
2021 – Editorial Board Member, Translational Oncology
2021 – Editorial Board Member, Nutraceuticals
2020 – Editorial Board Member, Cancers
2020 – Section Editor, Current Nutraceuticals
2019 – Editorial Board Member, Current Molecular Medicine

Research Focus

In 1975, Dr. Yamaguchi elucidated the role of liver in the regulation of blood calcium homeostasis and proposed that the liver is a novel target organ of calcitonin, a calcium-regulating hormone. This finding was originally published in Endocrinology (USA). In the course of this research, in 1978, Dr. Yamaguchi discovered a novel protein (gene), located on the X chromosome named "regucalcin" (gene symbol; rgn in PubMed). Regucalcin was shown to play a multifunctional role in various types of cells and tissues and to have a pathophysiological role in various diseases, including diabetes, osteoporosis, Parkinson’s and Alzheimer’s diseases, and malignancies in human subjects. Furthermore, in 2001, while studying transcriptional regulation of regucalcin gene expression, Dr. Yamaguchi et al. discovered a novel protein, called RGPR-p117 (regucalcin gene promoter region related protein; gene symbol; rgpr-p117 in PubMed), which binds to the promoter region of the regucalcin gene.

Since 2013, Dr. Yamaguchi has focused on cancer research to elucidate a potential role of regucalcin as a suppressor in cell growth and carcinogenesis in human subjects. Of note, many studies with proteomics and multiple gene expression profiles demonstrated that the regucalcin gene expression was uniquely downregulated in the tumor tissues of various types of human cancer patients, and that survival was prolonged with high expression of regucalcin in the tumor tissues of patients. Our translational studies demonstrated that overexpressed regucalcin prevented cancer cell growth. Regucalcin was proposed to play a crucial role as a novel suppressor in various types of human malignancies, providing a new strategy with the gene delivery system for cancer therapy. Recently, Dr. Yamaguchi has focused on the involvement of RGPR-p117 in implicating regucalcin gene expression in human cancer.

In addition, Dr. Yamaguchi is engaged in research of the role of medical food factors (nutraceuticals) in the treatment of cancer. Currently, therapeutic agents for bone metastasis and bone lesion are poorly developed. To date, Dr. Yamaguchi et al. have found that the botanical factor curcumin and p-hydroxycinnamic acid, and the marine factor 3,5-dihydroxy-4-methoxybenzyl alcohol inhibit cancer bone metastasis and related bone lesion in vitro and in vivo. These molecules are proposed to be a useful tool as a lead compound in the development of novel anticancer drugs for treatment of metastatic bone cancer.

Selected Publications

Yamaguchi M, Murata T, Ramos JW. (2023). The overexpressed regucalcin represses the growth via regulating diverse pathways linked to EGF signaling in human ovarian cancer SK-OV-3 cells: Involvement of extracellular regucalcin. Life Sciences 314:121328.

Yamaguchi M, Hashimoto K, Jijiwa M, Murata T. (2023). The inflammatory macrophages repress the growth of bone metastatic human prostate cancer cells via TNF-α and IL-6 signaling: Involvement of cell signaling regulator regucalcin. Cellular Signalling 107:110663 .

Yamaguchi M, Ghanem NZ, Hashimoto K, Ramos JW, Murata T. (2022). The overexpressed transcription factor RGPR-p117 suppresses the proliferation of normal rat kidney proximal tubular epithelial NRK-52E cells: Involvement of diverse signaling pathways. Life Sciences 306: 120795.

Yamaguchi M, Osuka S, Murata T, Ramos JW. (2021). Progression-free survival of prostate cancer patients is prolonged with a higher regucalcin expression in the tumor tissues: Overexpressed regucalcin suppresses the growth and bone activity in human prostate cancer cells. Transl Oncol;14:100955. PMID: 33232921.Doi.10.1016/j.tranon.2020.100955.

Yamaguchi M. (2013). Suppressive role of regucalcin in liver cell proliferation: Involvement in carcinogenesis. Cell Proliferation; 46:243-253. [Review]. PMID:23692083. PMCID: PMC6496855. Doi:10.1111/cpr.12036.

Yamaguchi M. (2017). The Role of Regucalcin in Cell Homeostasis and Disorder. New York, USA, Nova Science Publishers, Inc. Chapters 1-18, p.1-275. [Book]. ISBN: 978-1536105117; ISBN: 1536105112.

Publication list via Google Scholar

Publication list via NIH my Bibliography (PubMed)